Cargando…

Netupitant and palonosetron trigger NK(1) receptor internalization in NG108-15 cells

Current therapy for chemotherapy-induced nausea and vomiting includes the use of both 5-HT(3) and NK(1) receptor antagonists. Acute emesis has largely been alleviated with the use of 5-HT(3) receptor antagonists, while an improvement in preventing delayed emesis has been achieved with NK(1) receptor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thomas, Ajit G., Stathis, Marigo, Rojas, Camilo, Slusher, Barbara S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112047/ https://www.ncbi.nlm.nih.gov/pubmed/24969614 http://dx.doi.org/10.1007/s00221-014-4017-7

Ejemplares similares

Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
por: Shirley, Matt
Publicado: (2021)

Correction to: Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
por: Shirley, Matt
Publicado: (2021)

Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron
por: Lorusso, Vito
Publicado: (2016)

Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant–palonosetron combination
por: Janicki, Piotr K
Publicado: (2016)

Different modes of growth cone collapse in NG 108-15 cells
por: Rauch, Philipp, et al.
Publicado: (2013)

Development of a primary microglia screening assay and its use to characterize inhibition of system x(c)(-) by erastin and its analogs
por: Figuera-Losada, Mariana, et al.
Publicado: (2017)

The First Oral Fixed-Dose Combination of Netupitant and Palonosetron for the Treatment of Chemotherapy-Induced Nausea and Vomiting
por: Coyne, Joseph W.
Publicado: (2016)

Drug–drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data
por: Natale, James J, et al.
Publicado: (2015)

Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA)
por: Lorusso, Vito, et al.
Publicado: (2020)

Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice
por: Aapro, Matti, et al.
Publicado: (2022)

Proteomics Analysis of Normal and Senescent NG108-15 Cells: GRP78 Plays a Negative Role in Cisplatin-Induced Senescence in the NG108-15 Cell Line
por: Li, Wei, et al.
Publicado: (2014)

Profile of Antiemetic Activity of Netupitant Alone or in Combination with Palonosetron and Dexamethasone in Ferrets and Suncus murinus (House Musk Shrew)
por: Rudd, John A., et al.
Publicado: (2016)

Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)
por: Baron-Hay, Sally, et al.
Publicado: (2019)

Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)
por: Navari, Rudolph M
Publicado: (2014)

Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic
por: Hesketh, Paul J., et al.
Publicado: (2017)

Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy‐Induced Nausea and Vomiting
por: Gilmore, James, et al.
Publicado: (2018)

Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective
por: Nilsson, Jonas, et al.
Publicado: (2022)

Safety and efficacy of netupitant/palonosetron and dexamethasone in classical Hodgkin’s lymphoma patients with inadequate chemotherapy-induced nausea and vomiting prophylaxis with palonosetron and dexamethasone: a single-center real-life experience
por: Zilioli, Vittorio R, et al.
Publicado: (2020)

Dexamethasone‐Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High‐Dose Cisplatin: A Randomized Noninferiority Study
por: Celio, Luigi, et al.
Publicado: (2021)

Glutamate carboxypeptidase activity in human skin biopsies as a pharmacodynamic marker for clinical studies
por: Rojas, Camilo, et al.
Publicado: (2011)

NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK
por: Cawston, Helene, et al.
Publicado: (2017)

Simulation of the oxidative metabolization pattern of netupitant, an NK(1) receptor antagonist, by electrochemistry coupled to mass spectrometry
por: Chira, Ruxandra, et al.
Publicado: (2021)

Voltage-gated sodium channel expression and action potential generation in differentiated NG108-15 cells
por: Liu, Jinxu, et al.
Publicado: (2012)

Allosteric Glutaminase Inhibitors Based on a 1,4-Di(5-amino-1,3,4-thiadiazol-2-yl)butane Scaffold
por: Zimmermann, Sarah C., et al.
Publicado: (2016)

Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial
por: Spinelli, Tulla, et al.
Publicado: (2014)

Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India
por: Vaswani, Bharat, et al.
Publicado: (2020)

Simultaneous recording of electrical activity and the underlying ionic currents in NG108-15 cells cultured on gold substrate
por: Acosta-García, Ma. Cristina, et al.
Publicado: (2018)

Selective CNS Uptake of the GCP-II Inhibitor 2-PMPA following Intranasal Administration
por: Rais, Rana, et al.
Publicado: (2015)

Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study
por: Caputo, Roberta, et al.
Publicado: (2020)

Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin’s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation
por: Di Renzo, Nicola, et al.
Publicado: (2021)

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
por: Aapro, Matti, et al.
Publicado: (2016)

Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience
por: Loteta, Barbara, et al.
Publicado: (2021)

The Effectiveness of an Oral Fixed-Dose Combination of Netupitant and Palonosetron (NEPA) in Patients With Multiple Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Observational Indian Study
por: Vaswani, Bharat, et al.
Publicado: (2022)

Pentylenetetrazol modulates redox system by inducing addicsin translocation from endoplasmic reticulum to plasma membrane in NG108-15 cells
por: Ikemoto, Mitsushi J., et al.
Publicado: (2017)

Ion Channel Drugs Suppress Cancer Phenotype in NG108-15 and U87 Cells: Toward Novel Electroceuticals for Glioblastoma
por: Mathews, Juanita, et al.
Publicado: (2022)

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
por: Hesketh, P. J., et al.
Publicado: (2014)

Effects of Ginsenoside Rg1 on the Expression of Toll-Like Receptor 3, 4 and Their Signalling Transduction Factors in the NG108-15 Murine Neuroglial Cell Line
por: Zhao, Bao-Sheng, et al.
Publicado: (2014)

Anti-emetic Action of the Brain-Penetrating New Ghrelin Agonist, HM01, Alone and in Combination With the 5-HT(3) Antagonist, Palonosetron and With the NK(1) Antagonist, Netupitant, Against Cisplatin- and Motion-Induced Emesis in Suncus murinus (House Musk Shrew)
por: Rudd, John A., et al.
Publicado: (2018)

Netupitant, a Potent and Highly Selective NK(1) Receptor Antagonist, Alleviates Acetic Acid-Induced Bladder Overactivity in Anesthetized Guinea-Pigs
por: Palea, Stefano, et al.
Publicado: (2016)

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
por: Gralla, R. J., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bnl37e67ml3bvaemufj7k0ti5a